Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors (NCT04989010) | Clinical Trial Compass
UnknownNot Applicable
Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors
China20 participantsStarted 2021-08-01
Plain-language summary
This is a single arm study to evaluate the safety and biodistribution of 89Zr-labeled anti-CLDN18.2 mAbs (89Zr-NY005) PET imaging in patients with CLDN18.2 positive solid tumors.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patients voluntarily signed informed consent, and be able to complete the trial according to the requirement of the scheme;
. Aged 18-80, male or female;
. The clinical diagnosis was gastric cancer, esophageal cancer and pancreatic cancer;
. Patients with biopsy-proven CLDN18.2 positive;
. Patients diagnosed with solid tumors confirmed by histopathology or cytology test;
. At least two measurable solid lesions has been examined by 18F-FDG PET/CT (RECIST1.1 standard);
. ECOG score ≤ 0\~3; Life expectancy of at least 3 months;
. ALT, AST shall not exceed 3 times of the normal upper limit; Bun, Cr not exceed 1.5 times of the normal upper limit.
Exclusion criteria
. Recovery from major trauma (including surgery) within 4 weeks prior to study treatment;
. Patients with systemic or locally severe infections, or other serious coexisting diseases;
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Evaluation of tissue distribution of 89Zr-Anti-CLDN18.2 mAbs(NY005)
Timeframe: 1 year
2
Pharmacokinetic analysis of 89Zr-Anti-CLDN18.2 mAbs (NY005).
Timeframe: 1 year
3
Dosimetry estimates of 89Zr-Anti-CLDN18.2 mAbs (NY005).